Delivering the Promise of Genetic Medicine

Transforming the field of genetic medicine — Incisive Genetics™ is at the forefront with its novel OMNIA™ delivery platform for gene editing therapy.

WHO WE ARE

Incisive Genetics Inc. (IG) is a Canadian biotech firm that is focused on developing its innovative Omnia™ lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe the proprietary Omnia™ platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy — the effective and safe delivery of active gene editing machinery into in vivo target tissues.

Learn more

PLAY VIDEO

OMNIA

There is a unique opportunity in the gene therapy space for development of a “true” platform delivery technology. We will develop therapeutics comprised of:our proprietary OmniaTM platform, active CRISPR proteins, such as Cas9, and the target-specific guideRNA (and DNA template molecules when required). Incisive Genetics’ OmniaTM platform is a proprietary, non-viral delivery method for CRISPR-based gene therapies.

Learn more

OMNIA™

There is a unique opportunity in the gene therapy space for development of a superior platform delivery technology. IG’s Omnia™ platform is a proprietary, non viral delivery method for CRISPR based gene therapies. We intend to continue developing therapeutics using our proprietary Omnia™ platform, active CRISPR proteins, such as Cas9, and the target-specific guide RNA (and DNA template molecules when required).

Learn more

LEARN MORE ABOUT WHO WE ARE

OUR TEAM

LEARN MORE ABOUT OUR TEAM

LATEST NEWS

READ OUR LATEST NEWS AND MEDIA

SCIENTIFIC ADVISORY BOARD

LEARN MORE ABOUT OUR BOARD